IgD型复发难治多发性骨髓瘤患者BCMA靶点再治疗1例报告并文献复习  

BCMA chimeric antigen receptor T cells therapy re-treatment of a patient with recurrent/refractory IgDmultiplemyeloma:Acase reportand literature review

作　　者：顾思楠 强琬婷 卢静 冯中原 杜鹃 Gu Sinan;Qiang Wanting;Lu Jing;Feng Zhongyuan;Du Juan(Department of Hematology,The Myeloma&Lymphoma Center,The Second Affiliated Hospital of Naval Medical University(Shanghai Changzheng Hospital),Shanghai 200003,China)

机构地区：[1]海军军医大学第二附属医院(上海长征医院)血液病科,全军骨髓瘤与淋巴瘤疾病中心,上海200003

出　　处：《中华血液学杂志》2024年第10期951-955,共5页Chinese Journal of Hematology

摘　　要：多发性骨髓瘤(MM)是一种恶性浆细胞疾病,目前仍无法治愈。近年来,新药不断问世,与传统治疗相比,以B细胞成熟抗原(BCMA)为靶点的新药极大地改善了MM的疗效及预后。本文报道1例BCMA×CD3双特异性抗体治疗失败的IgD型复发难治MM患者,经过七线治疗,再次接受基于BCMA靶点的CAR-T细胞治疗后获得深度缓解,并进行相关文献复习,以期提高临床医师对复发难治MM患者BCMA靶点再治疗的认识。Multiple myeloma(MM)is a malignant plasma cell disease that currently cannot be cured.Several new drugs have continuously been introduced in the recent years.New drugs targeting B-cell maturation antigen(BCMA)have greatly improved the efficacy and prognosis of MM compared with traditional treatments.This article reports the case of an IgD type relapsed and refractory MM patient with poor efficacy of BCMAxCD3 bispecific antibody.The patient achieved deep remission after receiving BCMA-targeted CAR-T cell therapy after initial seven lines of treatment.Literature review was also conducted to improve the clinical physicians'understanding of BCMA target therapy for relapsed and refractory MM patients.

关 键 词：双特异性抗体 临床医师 IgD型 治疗失败 复发难治 BCMA B细胞成熟抗原 文献复习 

分 类 号：R733.3[医药卫生—肿瘤]